Tuesday, July 16, 2019

Regenarative Medicine - BJSTR Journal

Abstract

Statistics describes insufficient effectiveness of traditional methods of therapy in patients with #neurodestructive processes. Implementation of cell technologies in traumas and brain attacks increases effectiveness of recovery processes when standard therapy is combined with stem cells (SC) implantation. What is the reason for such positive demonstration of brain plasticity and activation of reparative processes? There are different opinions on that scope [1-4]. The answer is important for viability of cell technologies in recovery of neural network structures in #brain trauma. Local trauma in sensorimotor area of cerebral cortex was simulated in rats weighing 230g (n=9) in stereotaxic apparatus after #ketamine-xylazine-acepromazine anesthesia (55.6, 5.5 and 1.1, mg/kg, i/p, respectively). Culture of mesenchymal stem cells (MSC, 30000 per 1ml) was implanted into submucosa of nasal cavity in the amount of 100|il of culture medium. MSC were previously marked with FITC-labeled PH678. Slices 8|im in thickness were prepared in one week after decapitation, MSC distribution was visualized using Zeiss AxioVert 200M fluorescence microscope with Zeiss AxioCam HRm CCD camera. Dissociated culture of neuron-like cells of rat pups' (n=15) cerebral cortex was in vitro cultivated on glass matrix for one week. Surface of matrix was treated with #polymer (3,4 ethylenedioxythiophene). These in vitro experiments are necessary for analysis of transformation dynamics of dissociated neuron-like cells to neural network. Figure 1 shows diffuse distribution of fluorescent formations in sensorimotor brain area. The picture is associated with the Milky Way at night. So, Figure 1 demonstrates vast distribution of perineurally implanted MSC in the area of local brain trauma.

For more articles on BJSTR Journal please click on https://biomedres.us/



No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Discrepancies of Pediatric Data of BNT162b2 mRNA Covid-19 Vaccine in the Assessment Report of the European Medicines Agency

  Discrepancies of Pediatric Data of BNT162b2 mRNA Covid-19 Vaccine in the Assessment Report of the European Medicines Agency Clinical Effic...